Abstract
Leflunomide belongs in the group of disease-modifying anti-rheumatic drugs (DMARDs) used in the treatment of psoriatic, rheumatoid, and reactive arthritis. Approximately 20 % of patients will experience some adverse event, mainly weight loss, abdominal pain, and diarrhea. We describe the clinical, endoscopic, and histological findings in a patient with psoriatic arthritis (PA) who developed severe chronic diarrhea after drug use.
Original language | English |
---|---|
Pages (from-to) | 735-736 |
Number of pages | 2 |
Journal | Revista Espanola de Enfermedades Digestivas |
Volume | 113 |
Issue number | 10 |
DOIs | |
State | Published - Oct 2021 |
Keywords
- Chronic diarrhea
- Collagenous colitis
- Leflunomide